Lack Of Interchangeability No Barrier For Amjevita, Says Amgen Executive
Company Expects Product To Receive Designation Some Time After January Launch
Executive Summary
While Amgen’s Amjevita (adalimumab-atto) has yet to secure an interchangeability designation, company executives appear confident this will have little impact on their Humira biosimilar’s competitiveness overall.
You may also be interested in...
As Biosimilar Revenues Fall, Amgen Looks To Next Wave For Growth
With previously leading Amgen biosimilars such as Mvasi (bevacizumab) and Kanjinti (trastuzumab) seeing their sales decline, the firm is turning its attention to the next wave of biosimilars that will drive future growth.
Amgen Does Not Expect Big Enbrel Price Impact From US Humira Biosimilar Launches
Amgen will be first to launch a Humira biosimilar in the US with its Amgevita, but it and other adalimumab copies may add pressure to the company’s already declining top-seller Enbrel.
'Incorrect' To Assume Interchangeables Are Safer, More Effective Than Biosimilars, Says FDA
US FDA India country director Dr Sarah McMullen provides a fact check at a recent conclave to dispel the notion that interchangeable biosimilars are safer and more effective than other approved biosimilars.